Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and ...
THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) (Nasdaq: LXRX), today announced that, following the receipt of recent feedback from FDA, it is preparing ...
Shares of Lexicon Pharmaceuticals LXRX rose more than 5% on Tuesday after the company announced that the FDA accepted its resubmitted new drug application (NDA) seeking approval for sotagliflozin as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback